News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

International Stem Cell Corporation Signs Letter of Intent with BioTime (BTIM.PK), and Embryome Sciences, Inc. to Provide Unique Human Stem Cell Lines for Research Use


4/3/2008 8:36:00 AM

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO) and its wholly-owned subsidiary Lifeline Cell Technology (Lifeline) have signed a letter of intent with BioTime, Inc., (OTCBB:BTIM) (Emeryville, CA) and BioTime’s wholly-owned subsidiary Embryome Sciences, Inc., to jointly produce and distribute hundreds of new standardized human and animal stem cell lines, along with corresponding data and reagents. The mutual goal is to provide unique research tools for scientists seeking cures for human disease through regenerative medicine and pharmaceutical drug discovery.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES